Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study

OBJECTIVE: To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). METHODS: Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Denton, Christopher P., Hachulla, Éric, Riemekasten, Gabriela, Schwarting, Andreas, Frenoux, Jean‐Marie, Frey, Aline, Le Brun, Franck‐Olivier, Herrick, Ariane L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099416/
https://www.ncbi.nlm.nih.gov/pubmed/29193819
http://dx.doi.org/10.1002/art.40242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099416/
https://www.ncbi.nlm.nih.gov/pubmed/29193819
http://dx.doi.org/10.1002/art.40242

Ejemplares similares